Evoke Pharma, Inc. (EVOK)
EVOK Stock Price Chart
Explore Evoke Pharma, Inc. interactive price chart. Choose custom timeframes to analyze EVOK price movements and trends.
EVOK Company Profile
Discover essential business fundamentals and corporate details for Evoke Pharma, Inc. (EVOK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
25 Sept 2013
Employees
3.00
Website
https://www.evokepharma.comCEO
Matthew J. D'Onofrio MBA
Description
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
EVOK Financial Timeline
Browse a chronological timeline of Evoke Pharma, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 5 Nov 2025
Earnings released on 14 Aug 2025
EPS came in at -$0.62 falling short of the estimated -$0.45 by -37.78%, while revenue for the quarter reached $3.75M , missing expectations by -13.27%.
Earnings released on 13 May 2025
EPS came in at -$0.51 falling short of the estimated -$0.33 by -54.55%, while revenue for the quarter reached $3.08M , missing expectations by -7.11%.
Earnings released on 13 Mar 2025
EPS came in at -$0.49 falling short of the estimated -$0.25 by -96.00%, while revenue for the quarter reached $3.31M , beating expectations by +7.28%.
Earnings released on 7 Nov 2024
EPS came in at -$0.94 falling short of the estimated -$0.38 by -147.37%, while revenue for the quarter reached $2.65M , missing expectations by -13.94%.
Earnings released on 13 Aug 2024
EPS came in at -$0.93 falling short of the estimated -$0.72 by -29.17%, while revenue for the quarter reached $2.55M , missing expectations by -14.38%.
Stock split effective on 1 Aug 2024
Shares were split 1 : 12 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 May 2024
EPS came in at -$2.04 falling short of the estimated -$0.21 by -871.43%, while revenue for the quarter reached $1.74M , missing expectations by -18.90%.
Earnings released on 14 Mar 2024
EPS came in at -$7.08 falling short of the estimated -$0.50 by -1.32K%, while revenue for the quarter reached $1.68M , beating expectations by +2.82%.
Earnings released on 9 Nov 2023
EPS came in at -$6.12 falling short of the estimated -$0.62 by -887.10%, while revenue for the quarter reached $1.56M , missing expectations by -4.12%.
Earnings released on 10 Aug 2023
EPS came in at -$6.72 falling short of the estimated -$0.73 by -820.55%, while revenue for the quarter reached $1.13M , beating expectations by +2.85%.
Earnings released on 15 May 2023
EPS came in at -$8.04 falling short of the estimated -$0.58 by -1.29K%, while revenue for the quarter reached $810.41K , missing expectations by -18.96%.
Earnings released on 21 Mar 2023
EPS came in at -$6.36 falling short of the estimated $0.53 by -1.30K%, while revenue for the quarter reached $796.37K , missing expectations by -10.52%.
Earnings released on 9 Nov 2022
EPS came in at -$7.20 falling short of the estimated -$0.66 by -990.91%, while revenue for the quarter reached $832.10K , beating expectations by +45.47%.
Earnings released on 10 Aug 2022
EPS came in at -$8.52 falling short of the estimated -$0.60 by -1.32K%, while revenue for the quarter reached $461.80K , missing expectations by -20.38%.
Stock split effective on 23 May 2022
Shares were split 1 : 12 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 10 May 2022
EPS came in at -$10.09 falling short of the estimated -$5.77 by -75.00%, while revenue for the quarter reached $418.38K , missing expectations by -21.80%.
Earnings released on 8 Mar 2022
EPS came in at -$7.21 falling short of the estimated -$0.08 by -8.91K%, while revenue for the quarter reached $360.57K , missing expectations by -28.88%.
Earnings released on 10 Nov 2021
EPS came in at -$8.65 falling short of the estimated -$0.07 by -12.26K%, while revenue for the quarter reached $930.45K .
Earnings released on 12 Aug 2021
EPS came in at -$10.09 falling short of the estimated -$0.08 by -12.51K%, while revenue for the quarter reached $236.64K , beating expectations by +57.76%.
Earnings released on 12 May 2021
EPS came in at -$11.53 falling short of the estimated -$8.65 by -33.29%, while revenue for the quarter reached $90.42K , beating expectations by 0.00%.
Earnings released on 11 Mar 2021
EPS came in at -$12.97 falling short of the estimated -$5.76 by -125.17%, while revenue for the quarter reached $23.02K .
Earnings released on 10 Nov 2020
EPS came in at -$11.53 surpassing the estimated -$14.41 by +19.99%.
EVOK Stock Performance
Access detailed EVOK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.